Meeting summary - Patients and Consumers Working Party (PCWP) and Healthcare Professionals Working Party (HCPWP) meeting (2-3 July 2024)
European Medicines Agency (EMA) Patients' and Consumers' (PCWP) Working Party meeting, European Medicines Agency, Amsterdam, the Netherlands, 2 July 2024
Meeting summary - Patients and Consumers Working Party (PCWP) meeting (2 July 2024)
Human medicines European public assessment report (EPAR): Teriflunomide Mylan, teriflunomide, Date of authorisation: 09/11/2022, Revision: 3, Status: Authorised
Valproate : PRAC non-interventional imposed PASS final study report assessment report - EMEA/H/N/PSR/J/0043
Products Management Services (PMS) - Implementation of International Organization for Standardization (ISO) standards for the identification of medicinal products (IDMP) in Europe - Chapter 1
Paediatric Committee (PDCO): 23-26 July 2024, Online, European Medicines Agency, Amsterdam, the Netherlands, from 23 July 2024 to 26 July 2024
Agenda - PDCO agenda of the 23-26 July 2024 meeting
ACT EU consolidated advice pilots: information and training webinar for Applicants, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 17 July 2024, 15:00 (CEST) to 17 July 2024, 17:00 (CEST)
Orphan designation: 4-(4-Methyl-piperazin-1-yl)-N-{6-[2-(4-trifluoromethyl-benzyloxy)-ethoxy]-1H-indazol-3-yl}-benzamide hemioxalate Treatment of acute myeloid leukaemia, 21/03/2024 Positive